ClinicalTrials.gg
Active, not recruitingNCT05590468Updated Jan 26, 2026

A Study to Evaluate Vitamin B3 Derivative to Treat Mitochondrial Myopathy

A Phase 2 interventional study of Nicotinamide Riboside and Placebo in Mitochondrial Myopathy, sponsored by Ralitza Gavrilova. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-26.

Sponsored by Ralitza Gavrilova · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Mitochondrial Myopathies with a site in United States — 6 open to participants now, 8 under way, none of them phase 3. Mitochondrial Myopathies · United States.

Planned enrollment
9th of 12
34 · median 50
Started
2023
with 3 others
Phase 2
5 of 19
none open now
Registered
15th of 19
by date
Lead sponsor
1 of 19
Ralitza Gavrilova

Among the 19 studies in Mitochondrial Myopathies with a site in United States, this one is the 9th largest by planned enrollment of the 12 interventional ones that give a count, is one of 4 that started in 2023, is one of 5 in phase 2, and was the 15th registered.

Mitochondrial Myopathies

46 studies on the registry are indexed under Mitochondrial Myopathies; 14 are open to participants now.

Browse Mitochondrial Myopathies studies →

Open to participants now

6 of the 19 studies in Mitochondrial Myopathies with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 6 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 13 Mitochondrial Myopathies studies recruiting now, 8 (62%) set no upper age limit and 4 (31%) stop at 75 or younger; 6 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Mitochondrial Myopathies with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine the effects of Nicotinamide Riboside (NR) supplement in adult-onset symptoms of mitochondrial myopathy.

03

Conditions studied

  • Mitochondrial Myopathy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Biochemically and/or genetically confirmed or confirmed primary mitochondrial myopathy based on published diagnostic criteria.
  • Biochemically confirmed mitochondrial disorder would mean that the patient meets clinical criteria and has either or biochemical testing that supports the diagnosis.
  • Confirmed mitochondrial disorder means that the patient meets published clinical criteria for the diagnosis and has also had confirmatory genetic testing for the disorder type.
  • Agreed to avoid vitamin supplementation or nutritional products with vitamin B3 forms 14 days prior to the enrollment and during the study in order to not exceed 200 mg/day of vitamin B3 derivatives intake.
  • Female of agreed to use effective throughout the study.
  • Written, to participate in the study.

Exclusion criteria

Exclusion Criteria:

  • Unwilling to comply with the follow-up schedule.
  • Inability or refusal to give by the patient or a legally authorized representative.
  • Known pregnancy or breastfeeding.
  • Concurrent participation in another drug study or within of treatment.
  • Presence of other medical symptoms or condition, which may interfere with interpretation of outcome measures as determined by the study PI.

Clinical / Laboratory Exclusion Criteria:

  • Estimated (eGFR) \< 30 mL/min.
  • Patients in permanent Renal Replacement Therapy.
  • Serum alkaline phosphatase 50% above normal limit.
  • Serum 50% above normal limit.
  • Serum Thyroxine (T4) 50% above or below normal limit.
  • Serum Thyroid Stimulating Hormone (TSH) 50% above or below normal limit.
  • Severe anemia with \< 7g/dL.
  • Severe leukocytosis with WBC > 15,000/mm\^3.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Nicotinamide Riboside treatment group

    Subjects will receive vitamin B3 derivative Nicotinamide Riboside (NR) daily for 12 months

    Dietary Supplement: Nicotinamide Riboside

  • Placebo comparator
    Placebo Group

    Subjects will receive a placebo daily for 12 months

    Drug: Placebo

Interventions

  • Dietary supplementNicotinamide-beta-ribosideStudies of Nicotinamide-beta-ribosideNicotinamide-beta-riboside pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Vitamin B3 derivative; a total of 1000 mg/day in a regimen of 500mg every 12 hours by mouth (either fasting or fed)

  • DrugPlacebo

    Looks exactly like the study drug, but it contains no active ingredient

06

What researchers measure

Primary outcomes

  1. Changes in 6-Minute Walk Test Performance

    The 6-minute walk test (6MWT) quantifies the distance a person can walk in six minutes. Measured in meters.

    Time frame: Baseline, 6 months, 12 months

Secondary outcomes

  1. Change in skeletal muscle function

    Measured using the Short Physical Performance Battery (SPPB) score based on timed measures of standing balance, walking speed and ability to rise from a chair. Each of the 3 performance measures will be assigned a score ranging from 0 to 4, with 4 indicating the highest level of performance and 0 the inability to complete the test. A summary score (range 0-12) will be subsequently calculated by adding the 3 scores.

    Time frame: Baseline, 6 months, 12 months

  2. Change in skeletal muscle strength

    Measured using the strength one repetition maximum (1RM leg press) defined as the maximal weight an individual can lift for only one repetition with correct technique.

    Time frame: Baseline, 6 months, 12 months

  3. Change in isometric strength of trunk flexors

    Assessed by generated maximum force against a stationary dynamometer reported in kilograms of force. Trunk flexion strength tested in the supine position with knees slightly bent, arms at side and head in midline. The base of the dynamometer will be placed on the middle of the sternum and the patient will be instructed to exert isometric force by lifting both scapula off the plinth.

    Time frame: Baseline, 6 months, 12 months

  4. Change in isometric strength of trunk extensor muscle

    Assessed by generated maximum force against a stationary dynamometer reported in kilograms of force. Trunk extensor muscle strength tested in prone position. The base of the dynamometer will be placed at the level of the T4 spine and the patient instructed to generate an isometric force by lifting the chest off the plinth. After sufficient practice in the standardized positions, 5 trials will be recorded in each position.

    Time frame: Baseline, 6 months, 12 months

  5. Change in maximal oxygen uptake (VO2 max)

    Maximal oxygen uptake (VO2 max) test measures the maximum rate of oxygen consumption during incremental exercise (exercise of increasing intensity) and reflects the cardiorespiratory fitness of an individual. Reported in ml/kg/min.

    Time frame: Baseline, 6 months, 12 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2023 (actual). Primary completion is estimated for Nov 2026, 42 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 19, 2022
First posted
Oct 21, 2022
StartActual
May 26, 2023
Primary completionEst.
Nov 2026
CompletionEst.
Nov 2026
Last update
Jan 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 26, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05590468
Lead sponsor
Ralitza Gavrilova
Responsible party
Ralitza Gavrilova (Regulatory Sponsor, Mayo Clinic) — Sponsor-investigator
First posted
Oct 21, 2022
Start date
May 26, 2023
Primary completion
Nov 2026 (estimated)
Completion
Nov 2026 (estimated)
Last update
Jan 26, 2026

Study contacts

Ralitza H. Gavrilova, MD
principal investigator · Mayo Clinic

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nicotinamide-beta-riboside

Start the discussion